Literature DB >> 28196027

MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Stellate Cells.

Koetsu Inoue1, Hideo Ohtsuka, Masanori Tachikawa, Fuyuhiko Motoi, Masahiro Shijo, Daisuke Douchi, Shuhei Kawasaki, Kei Kawaguchi, Kunihiro Masuda, Koji Fukase, Takeshi Naitoh, Yu Katayose, Shinichi Egawa, Michiaki Unno, Tetsuya Terasaki.   

Abstract

OBJECTIVES: Platelet-derived growth factor receptor beta (PDGFRβ) and hepatocyte growth factor receptor (MET) expressed on pancreatic stellate cells (PSCs) are suggested as important components modulating the interactions between pancreatic cancer cells (PCCs) and PSCs. The objective of this study is to clarify the effect of MK2461, a multikinase inhibitor targeting MET and PDGFRβ, on the interaction between PCCs and PSCs.
METHODS: In this study, we profiled the expression of receptor tyrosine kinases (including PDGFRβ and MET) in pancreatic cancer with quantitative targeted absolute proteomics using liquid chromatography tandem mass spectrometry. In addition, the effect of MK2461 on PCC-PSC interaction was investigated using PSCs prepared from pancreatic cancer tissues.
RESULTS: In PSCs, PDGFRβ and MET were upregulated compared with other receptor tyrosine kinases. Conditioned medium from PSCs promoted the proliferation of PCCs, and vice versa. Moreover, MK2461 suppressed the effects of conditioned medium on PCCs and PSCs. Finally, MK2461 significantly inhibited tumor growth in mice coinjected with PCCs and PSCs.
CONCLUSIONS: The PDGFRβ and MET may play a critical role in the interaction between PCCs and PSCs, which was modulated by MK2461. Therefore, MK2461 may have therapeutic potential in the treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28196027     DOI: 10.1097/MPA.0000000000000778

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

Review 1.  Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting.

Authors:  Nardeen Perko; Shaker A Mousa
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

2.  Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells.

Authors:  Omidreza Firuzi; Pei Pei Che; Btissame El Hassouni; Mark Buijs; Stefano Coppola; Matthias Löhr; Niccola Funel; Rainer Heuchel; Ilaria Carnevale; Thomas Schmidt; Giulia Mantini; Amir Avan; Luciano Saso; Godefridus J Peters; Elisa Giovannetti
Journal:  Cancers (Basel)       Date:  2019-05-08       Impact factor: 6.639

3.  Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.

Authors:  Shuichi Aoki; Koetsu Inoue; Sebastian Klein; Stefan Halvorsen; Jiang Chen; Aya Matsui; Mohammad R Nikmaneshi; Shuji Kitahara; Tai Hato; Xianfeng Chen; Kazumichi Kawakubo; Hadi T Nia; Ivy Chen; Daniel H Schanne; Emilie Mamessier; Kohei Shigeta; Hiroto Kikuchi; Rakesh R Ramjiawan; Tyge Ce Schmidt; Masaaki Iwasaki; Thomas Yau; Theodore S Hong; Alexander Quaas; Patrick S Plum; Simona Dima; Irinel Popescu; Nabeel Bardeesy; Lance L Munn; Mitesh J Borad; Slim Sassi; Rakesh K Jain; Andrew X Zhu; Dan G Duda
Journal:  Gut       Date:  2021-01-11       Impact factor: 31.793

Review 4.  Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.

Authors:  Vida Mashayekhi; Orsola Mocellin; Marcel H A M Fens; Gerard C Krijger; Lodewijk A A Brosens; Sabrina Oliveira
Journal:  Theranostics       Date:  2021-08-25       Impact factor: 11.556

5.  The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.

Authors:  Zeyu Wang; Yuze Liu; Yuyao Mo; Hao Zhang; Ziyu Dai; Xun Zhang; Weijie Ye; Hui Cao; Zhixiong Liu; Quan Cheng
Journal:  Front Immunol       Date:  2021-09-13       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.